Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

141. Surgical adverse events: a systematic review

Surgical adverse events: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

142. Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: a systematic review

Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

143. Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs. (Abstract)

Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs. 23552833 2013 05 13 2013 04 04 1539-3704 158 6 2013 Mar 19 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs. JC7 10.7326/0003-4819-158-6-201303190-02007 de Leeuw Peter W PW Maastricht University Medical Centre and Cardiovascular Research

2013 Annals of Internal Medicine

144. Adverse events associated with EUS and EUS with FNA

Adverse events associated with EUS and EUS with FNA GUIDELINE Adverse events associated with EUS and EUS with FNA This is one of a series of statements discussing the use of GI endoscopy in common clinical situations. The Stan- dards of Practice Committee of the American Society for Gastrointestinal Endoscopy prepared this text. In prepar- ing this document, a search of the medical literature was performed by using PubMed. Additional references were obtained from the bibliographies (...) nodes, often in close proximity to large vascular structures. EUS uses dedicated echoendoscopes that have unique optical and mechanical properties be- yond the addition of a US transducer. The incidence and types of adverse events associated with EUS differ from those seen with other endoscopic procedures and are attributable to the use of FNA. This guideline focuses on the adverse events speci?cally associated with EUS and EUS-FNA. Adverse events associated with sedation and standard endoscopic

2013 American Society for Gastrointestinal Endoscopy

145. Cohort study: Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin

Cohort study: Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Article Text Aetiology Cohort study Lack

2013 Evidence-Based Medicine

146. Review: SSRIs and TCAs equally effective at treating chronic depression and dysthemia; SSRIs are associated with fewer adverse events than TCAs

Review: SSRIs and TCAs equally effective at treating chronic depression and dysthemia; SSRIs are associated with fewer adverse events than TCAs Review: SSRIs and TCAs equally effective at treating chronic depression and dysthemia; SSRIs are associated with fewer adverse events than TCAs | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we (...) are associated with fewer adverse events than TCAs Article Text Therapeutics Review: SSRIs and TCAs equally effective at treating chronic depression and dysthemia; SSRIs are associated with fewer adverse events than TCAs Statistics from Altmetric.com Question Question: What is the efficacy and acceptability of selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) in the treatment of chronic depression? Outcomes: Primary efficacy outcome: response to treatment, defined as ≥50

2013 Evidence-Based Mental Health

147. Adults with psychosis or psychotic experiences may report adverse life events prior to the onset of symptoms but direction of causality cannot be inferred

Adults with psychosis or psychotic experiences may report adverse life events prior to the onset of symptoms but direction of causality cannot be inferred Adults with psychosis or psychotic experiences may report adverse life events prior to the onset of symptoms but direction of causality cannot be inferred | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adults with psychosis or psychotic experiences may report adverse life events

2013 Evidence-Based Mental Health

148. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

149. Procedural Sedation for Diagnostic Imaging in Children by Pediatric Hospitalists using Propofol: Analysis of the Nature, Frequency, and Predictors of Adverse Events and Interventions

Procedural Sedation for Diagnostic Imaging in Children by Pediatric Hospitalists using Propofol: Analysis of the Nature, Frequency, and Predictors of Adverse Events and Interventions PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2012 PedsCCM Evidence-Based Journal Club

150. Review: Varenicline for tobacco cessation does not increase CV serious adverse events. (Abstract)

Review: Varenicline for tobacco cessation does not increase CV serious adverse events. 22910956 2012 10 19 2012 08 22 1539-3704 157 4 2012 Aug 21 Annals of internal medicine Ann. Intern. Med. ACP Journal Club: review: varenicline for tobacco cessation does not increase CV serious adverse events. JC2-2 10.7326/0003-4819-157-4-201208210-02002 Krebs Paul P VA New York Harbor Healthcare System, New York University School of Medicine, New York, New York, USA. Sherman Scott E SE eng Comment Journal

2012 Annals of Internal Medicine

151. Review: Lithium is associated with adverse events in patients with mood disorders. (Abstract)

Review: Lithium is associated with adverse events in patients with mood disorders. 22801701 2012 09 24 2012 07 17 1539-3704 157 2 2012 Jul 17 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Review: lithium is associated with adverse events in patients with mood disorders. JC2-10 10.7326/0003-4819-157-2-201207170-02010 Preda Adrian A eng Comment Journal Article United States Ann Intern Med 0372351 0003-4819 Lancet. 2012 Feb 25;379(9817):721-8 22265699 2012 7 18 6 0 2012 7 18 6 0

2012 Annals of Internal Medicine

152. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis

Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

153. Discontinuation of hormone replacement therapy after myocardial infarction and short term risk of adverse cardiovascular events: nationwide cohort study. Full Text available with Trip Pro

Discontinuation of hormone replacement therapy after myocardial infarction and short term risk of adverse cardiovascular events: nationwide cohort study. To assess the risk of adverse cardiovascular events in women who discontinue hormone replacement therapy after myocardial infarction compared with those who continue.Nationwide register based cohort study.All hospitals in Denmark.All 3322 women aged 40 years or over who survived 30 days after a myocardial infarction and were prescribed hormone (...) % confidence interval 0.68 to 1.19), cardiovascular mortality (1.21, 0.90 to 1.62), or all cause mortality (1.22, 0.97 to 1.53) than women who continued use. However, discontinuation of vaginal oestrogen was associated with a lower risk of reinfarction (hazard ratio 0.54, 0.34 to 0.86).No certain conclusions can be drawn regarding increased or decreased risk of adverse cardiovascular events with continuing hormone replacement therapy after myocardial infarction. The results rule out neither a modest

2012 BMJ

154. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials

The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

155. Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis

Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

156. Adverse events of upper GI endoscopy

Adverse events of upper GI endoscopy GUIDELINE Adverse events of upper GI endoscopy This is one of a series of statements discussing the use of GI endoscopy in common clinical situations. The Stan- dards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE) prepared this text. In preparing this document, a search of the medical liter- ature was performed by using PubMed. Additional refer- ences were obtained from the bibliographies of the identi- ?ed articles (...) to take a course of action that varies from this document. Upper GI (UGI) endoscopy is commonly performed andcarriesalowriskofadverseevents.Largeseriesreport adverse event rates of 1 in 200 to 1 in 10,000 and mortality rates ranging from none to 1 in 2000. 1-6 Data collected from the Clinical Outcomes Research Initiative database show a cardiopulmonary event rate of 1 in 170 and a mortality rate of 1 in 10,000 from among 140,000 UGI endoscopicprocedures. 7 Thevariabilityinratesofadverse events may

2012 American Society for Gastrointestinal Endoscopy

157. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer

A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

158. Fingolimod (Gilenya?): not recommended for patients at known risk of cardiovascular adverse events

Fingolimod (Gilenya?): not recommended for patients at known risk of cardiovascular adverse events Fingolimod (Gilenya▼): not recommended for patients at known risk of cardiovascular adverse events - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Fingolimod (Gilenya▼): not recommended for patients at known risk of cardiovascular adverse events New advice for extended early monitoring for those with significant bradycardia or heart block after first dose. Published 11 December (...) for fingolimod in . We now provide updated advice to avoid use in high-risk groups and extend monitoring in some patients. The latest advice follows further review of worldwide data including 15 cases of sudden or unexplained death with fingolimod. Most of the deaths and cardiovascular events had occurred in patients with either a history of cardiovascular problems, such as atrioventricular block or bradycardia, or those who were also taking other medicines. However the data reviewed were not conclusive

2012 MHRA Drug Safety Update

159. Supportive treatment for cancer - Part 2: Prevention and treatment of adverse events related to chemotherapy and radiotherapy

Supportive treatment for cancer - Part 2: Prevention and treatment of adverse events related to chemotherapy and radiotherapy Supportive treatment for cancer - Part 2: Prevention and treatment of adverse events related to chemotherapy and radiotherapy Supportive treatment for cancer - Part 2: Prevention and treatment of adverse events related to chemotherapy and radiotherapy Verleye L, van de Wetering F, Heus P, Scholten R, Vlayen J Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Verleye L, van de Wetering F, Heus P, Scholten R, Vlayen J. Supportive treatment for cancer - Part 2: Prevention and treatment of adverse events related to chemotherapy and radiotherapy. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 191C. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic

2012 Health Technology Assessment (HTA) Database.

160. Use of ADHD drugs in children and young adults does not increase risk of serious cardiovascular adverse events compared with non-use

Use of ADHD drugs in children and young adults does not increase risk of serious cardiovascular adverse events compared with non-use Use of ADHD drugs in children and young adults does not increase risk of serious cardiovascular adverse events compared with non-use | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Use of ADHD drugs in children and young adults does not increase risk of serious cardiovascular adverse events compared

2012 Evidence-Based Mental Health